Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis | Zendy

Nathella Pavan Kumar | Zendy; Kadar Moideen | Zendy; Arul Nancy | Zendy; Vijay Viswanathan | Zendy; Kannan Thiruvengadam | Zendy; Shanmugam Sivakumar | Zendy; Syed Hissar | Zendy; Diir | Zendy; Vaithilingam V. Banurekha | Zendy; Hardy Kornfeld | Zendy; Subash Babu | Zendy

Open Access

Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis

Author(s) -

Nathella Pavan Kumar,

Kadar Moideen,

Arul Nancy,

Vijay Viswanathan,

Kannan Thiruvengadam,

Shanmugam Sivakumar,

Syed Hissar,

Diir,

Vaithilingam V. Banurekha,

Hardy Kornfeld,

Subash Babu

Publication year - 2020

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2020.27754

Subject(s) - matrix metalloproteinase , matrix metalloproteinase 9 , medicine , adverse effect , tissue inhibitor of metalloproteinase , metalloproteinase , tuberculosis , matrix (chemical analysis) , matrix metalloproteinase inhibitor , gastroenterology , pathology , chemistry , chromatography

This case-control study examines the value of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) as biomarkers of treatment outcomes among patients with pulmonary tuberculosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research